Scarica l'app Stockscreener
10.19
7.28%
-0.80
Dopo l'orario di chiusura:
10.00
-0.19
-1.86%
Precedente Chiudi:
$10.99
Aprire:
$11.03
Volume 24 ore:
2.13M
Relative Volume:
1.03
Capitalizzazione di mercato:
$915.54M
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-3.4426
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
-4.23%
1M Prestazione:
-8.69%
6M Prestazione:
-38.73%
1 anno Prestazione:
-51.41%
Intervallo 1D:
$10.10
$11.11
Intervallo di 1 settimana:
$9.665
$11.48
Portata 52W:
$9.66
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Confronta SNDX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
10.19 | 915.54M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Voya Investment Management LLC Sells 45,352 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals Appoints Nicholas Botwood Chief Medical Officer - marketscreener.com
B. Riley Has Positive Outlook for SNDX Q2 Earnings - MarketBeat
SNDX Appoints New Head of Research and Development | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as - GlobeNewswire
I Have a Prescription for These Two Biopharmas That Fell After Earnings - TheStreet Pro
Synlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York - GuruFocus
Granahan Investment Management LLC Has $11.97 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Cubist Systematic Strategies LLC Invests $4.73 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Crestline Management LP Has $9.43 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Scotiabank Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Bayesian Capital Management LP Invests $370,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Marshall Wace LLP Sells 977,280 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Algert Global LLC Buys 310,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - Yahoo Finance
Syndax Announces Participation in May Investor Conferences - The Manila Times
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results - simplywall.st
Avidity Partners Management LP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX: Syndax Reveals Significant Phase 2 Trial Results for Revumenib | SNDX Stock News - GuruFocus
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $36.20 - MarketBeat
Syndax Announces Publication of Pivotal Revumenib Data in - GlobeNewswire
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - Yahoo Finance
Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call - TipRanks
SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenhei - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News - GuruFocus
Scotiabank raises Syndax stock target to $17 on strong sales By Investing.com - Investing.com Canada
Syndax (SNDX) Price Target Increased by BofA Following Promising Updates | SNDX Stock News - GuruFocus
BofA raises Syndax stock price target to $26 on strong Q1 update - Investing.com Canada
Syndax Pharmaceuticals Q1 Loss Widens - marketscreener.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highligh - GuruFocus
SNDX Reports Strong Revenue and Cash Position, Focuses on Growth - GuruFocus
Syndax Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2025 EPS estimates - Investing.com Canada
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Syndax Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax: Q1 Earnings Snapshot - MySA
Syndax Pharmaceuticals earnings beat by $0.26, revenue topped estimates - Investing.com Canada
Syndax Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.98 Beats Estimates, Revenue Surges to $20 Million - GuruFocus
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):